Revenue soars 25% on broad listing

Posted 7 July 2026 AM

A long fight for a new type of PBS listing has shown an almost immediate result in the reimbursement figures.

In March this year BMS scored a multi-indication PBS listing for immunotherapy drugs Opdivo and Yervoy, the first such listing around the globe.

To see the whole article, please login

Popular

Blockbusters stuck in PBS limbo

Pharma Wonderland opens in Sydney

Next era of blockbusters unveiled

New FY brings fresh career start

Latest Jobs

Trade Marketing Manager

Customer Service Representative

Clinical Trial Investigator

Senior Medical Receptionist - 2IC

Customer Service Administrator

See all...

Pharma in Focus Jobs

Marketing & Communications (2)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Head of Access, Sustainability & External Engagement - Melbourne

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (8)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now